Insulin-like growth factor 1

Bortvedt, Sarah F.; Lund, P. Kay

doi:10.1097/mog.0b013e32835004c6

Cited by 66 publications

(34 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of our study are relevant in that IGF1 is an important initiator of cellular repair processes, induces intestinal and linear growth, and may be linked to chronic inflammatory gastrointestinal pathway [38,39]. Also, IGF1 was shown to have a protective effect against inflammation in the bowel [40] and found to be therapeutic in patients with inflammatory bowel disease [40-42].…”

Section: Resultsmentioning

confidence: 98%

Sleep quality, BDNF genotype and gene expression in individuals with chronic abdominal pain

et al. 2014

View full text Add to dashboard Cite

BackgroundSleep quality and genetics may contribute to the etiology of gastrointestinal (GI) symptoms. Individuals with impaired sleep often have a number of associated symptoms including chronic abdominal pain (CAP). The current study examined the interactions of brain-derived neurotrophic factor (BDNF) genotype with sleep quality in persons with CAP and healthy controls. In addition, associations among sleep quality, BDNF genotype, and gene expression were explored in the participants.MethodsData were collected on 59 participants (46% male, 61% White, 26.9 ± 6.6 years; CAP (n=19) and healthy controls (n=40)). Participants with CAP reported poorer sleep quality compared to healthy controls. BDNF genotype, categorized as Val/Val homozygotes versus the Met carriers.ResultsMicroarray analysis found twenty-four differentially expressed genes by a two-fold magnitude in participants with poor sleep quality compared to good sleep quality, and seven differentially expressed genes comparing CAP to healthy control. Three specific genes in the pain group overlap with sleep quality, including insulin-like growth factor 1 (IGF1), spermatogenesis associated serine-rich 2-like (SPATS2L), and immunoglobulin heavy constant gamma 1 or mu (IGHG1/// IGHM). BDNF was shown to have an interaction effect with GI and sleep symptoms.ConclusionsParticipants with CAP reported poor sleep quality compared to healthy controls. The role of the BDNF Met allele on differential gene expression was not distinct as main factor, but impacted interactions with sleep quality and CAP. Down-regulation of IGF1, SPATS2L, and IGHG1 expression may be related to the etiology of poor sleep quality and CAP.Trial registrationClinicaltrial.gov # NCT00824941Electronic supplementary materialThe online version of this article (doi:10.1186/s12920-014-0061-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 98%

Sleep quality, BDNF genotype and gene expression in individuals with chronic abdominal pain

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In summary, our study shows that an IGFBP3-mediated disruption of CoSCs linked to hyperglycemia is evident in DE. We suggest that circulating IGF-I/IGFBP3 represent a hormonal dyad that controls CoSCs and a therapeutic target for individuals with intestinal disorders caused by diabetes mellitus of long duration (Bondy et al, 1994; Bortvedt and Lund, 2012; Boucher et al, 2010). …”

Section: Discussionmentioning

confidence: 99%

Circulating IGF-I and IGFBP3 Levels Control Human Colonic Stem Cell Function and Are Disrupted in Diabetic Enteropathy

D’Addio

Rosa²,

Maestroni

et al. 2015

Cell Stem Cell

View full text Add to dashboard Cite

Summary The role of circulating factors in regulating colonic stem cells (CoSCs) and colonic epithelial homeostasis is unclear. Individuals with long-standing type 1 diabetes (T1D) frequently have intestinal symptoms, termed diabetic enteropathy (DE), though its etiology is unknown. Here, we report T1D patients with DE exhibit abnormalities in their intestinal mucosa and CoSCs, which fail to generate in vitro mini-guts. Proteomic profiling of T1D+DE patient serum revealed altered levels of insulin-like growth factor 1 (IGF-1) and its binding protein-3 (IGFBP3). IGFBP3 prevented in vitro growth of patient-derived organoids via binding its receptor TMEM219, in an IGF-1-independent manner, and disrupted in vivo CoSC function in a preclinical DE model. Restoration of normoglycemia in patients with long-standing T1D via kidney-pancreas transplantation or in diabetic mice by treatment with an ecto-TMEM219 recombinant protein normalized circulating IGF-1/IGFBP3 levels and reestablished CoSC homeostasis. These findings demonstrate that peripheral IGF-1/IGFBP3 control CoSCs and their dysfunction in DE.

show abstract

“…Unlike GLP-2, somatropin is not intestine-specific, and likely exerts its intestinal tropic effects via insulin-like growth factor 1 (55). In a study of 8 pediatric patients with SBS, daily subcutaneous somatropin therapy led to increased enteral intake, and 2 patients achieved enteral autonomy during the follow-up period of 12 months (56).…”

Section: Emerging Therapiesmentioning

confidence: 99%